KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Acquisitions (2016 - 2022)

Eli Lilly's Acquisitions history spans 11 years, with the latest figure at $327.2 million for Q4 2022.

  • For Q4 2022, Acquisitions changed N/A year-over-year to $327.2 million; the TTM value through Dec 2022 reached $327.2 million, down 56.22%, while the annual FY2022 figure was $327.2 million, 56.22% down from the prior year.
  • Acquisitions reached $327.2 million in Q4 2022 per LLY's latest filing, down from $747.4 million in the prior quarter.
  • In the past five years, Acquisitions ranged from a high of $6.9 billion in Q1 2019 to a low of $327.2 million in Q4 2022.
  • Average Acquisitions over 4 years is $2.2 billion, with a median of $798.3 million recorded in 2020.
  • Peak YoY movement for Acquisitions: crashed 87.72% in 2020, then dropped 12.0% in 2021.
  • A 4-year view of Acquisitions shows it stood at $6.9 billion in 2019, then plummeted by 87.72% to $849.3 million in 2020, then dropped by 12.0% to $747.4 million in 2021, then crashed by 56.22% to $327.2 million in 2022.
  • Per Business Quant, the three most recent readings for LLY's Acquisitions are $327.2 million (Q4 2022), $747.4 million (Q1 2021), and $849.3 million (Q1 2020).